HC Wainwright & Co. Reiterates Buy Rating on Biogen Inc. (BIIB)

Market Context

Biogen Inc. operates in the Healthcare sector. The stock currently trades at $252.63 with a market capitalization of $25.3B. The stock has gained 38.9% over the past 52 weeks.

Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Biogen Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Biogen Inc.

Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Nov 02, 2026	Guggenheim	Buy	N/A
Nov 02, 2026	HC Wainwright & Co.	Buy	N/A
Oct 29, 2026	Argus Research	Buy	N/A
Oct 29, 2026	Canaccord Genuity	Buy	N/A
Oct 29, 2026	TD Cowen	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View BIIB Stock Page